VIP impairs acquisition of the macrophage proinflammatory polarization profile

This study tested the hypothesis that vasoactive intestinal peptide (VIP) is able to modify the macrophage inflammatory profile, thus supporting its therapeutic role in autoimmune diseases. Macrophages are innate immune cells that display a variety of functions and inflammatory profiles in response to the environment that critically controls their polarization. Deregulation between the pro‐ and anti‐inflammatory phenotypes has been involved in different pathologies. Rheumatoid arthritis (RA) is an autoimmune disease, in which macrophages are considered central effectors of synovial inflammation, displaying a proinflammatory profile. VIP is a pleiotropic neuropeptide with proven anti‐inflammatory actions. As modulation of the macrophage phenotype has been implicated in the resolution of inflammatory diseases, we evaluated whether VIP is able to modulate human macrophage polarization. In vitro‐polarized macrophages by GM‐CSF (GM‐MØ), with a proinflammatory profile, expressed higher levels of VIP receptors, vasoactive intestinal polypeptide receptors 1 and 2 (VPAC1 and VPAC2, respectively), than macrophages polarized by M‐CSF (M‐MØ) with anti‐inflammatory activities. RA synovial macrophages, according to their GM‐CSF‐like polarization state, expressed both VPAC1 and VPAC2. In vitro‐generated GM‐MØ exposed to VIP exhibited an up‐regulation of M‐MØ gene marker expression, whereas their proinflammatory cytokine profile was reduced in favor of an anti‐inflammatory function. Likewise, in GM‐MØ, generated in the presence of VIP, VIP somehow changes the macrophages physiology profile to a less‐damaging phenotype. Therefore, these results add new value to VIP as an immunomodulatory agent on inflammatory diseases.

[1]  R. Ramhorst,et al.  Trophoblast cells primed with vasoactive intestinal peptide enhance monocyte migration and apoptotic cell clearance through αvβ3 integrin portal formation in a model of maternal-placental interaction. , 2015, Molecular human reproduction.

[2]  J. Rodríguez-Frade,et al.  Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect , 2015, Journal of leukocyte biology.

[3]  Joel W. Graff,et al.  A Systematic Approach to Identify Markers of Distinctly Activated Human Macrophages , 2015, Front. Immunol..

[4]  I. McInnes,et al.  Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases , 2015, Pharmacological Reviews.

[5]  Cristina Municio,et al.  Macrophages from the synovium of active rheumatoid arthritis exhibit an activin A‐dependent pro‐inflammatory profile , 2015, The Journal of pathology.

[6]  D. Ganea,et al.  The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases , 2015, Acta physiologica.

[7]  I. González-Álvaro,et al.  The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP , 2014, Journal of Molecular Medicine.

[8]  S. Goerdt,et al.  Macrophage activation and polarization: nomenclature and experimental guidelines. , 2014, Immunity.

[9]  M. Mellado,et al.  Vasoactive Intestinal Peptide Maintains the Nonpathogenic Profile of Human Th17-Polarized Cells , 2014, Journal of Molecular Neuroscience.

[10]  Yong-ming Yao,et al.  Macrophage Polarization in Inflammatory Diseases , 2014, International journal of biological sciences.

[11]  I. González-Álvaro,et al.  Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis , 2014, PloS one.

[12]  I. González-Álvaro,et al.  IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts. , 2013, Rheumatology.

[13]  M. Sweet,et al.  An mRNA atlas of G protein-coupled receptor expression during primary human monocyte/macrophage differentiation and lipopolysaccharide-mediated activation identifies targetable candidate regulators of inflammation. , 2013, Immunobiology.

[14]  W. Savino,et al.  Macrophage Resistance to HIV-1 Infection Is Enhanced by the Neuropeptides VIP and PACAP , 2013, PloS one.

[15]  M. Wolzt,et al.  VPAC1 receptor expression in peripheral blood mononuclear cells in a human endotoxemia model , 2013, Journal of Translational Medicine.

[16]  O. Fardel,et al.  Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. , 2013, Cellular immunology.

[17]  S. Biswas,et al.  Macrophage polarization and plasticity in health and disease , 2012, Immunologic Research.

[18]  Alberto Mantovani,et al.  Macrophage plasticity and polarization: in vivo veritas. , 2012, The Journal of clinical investigation.

[19]  C. Martínez,et al.  Effect of VIP on the balance between cytokines and master regulators of activated helper T cells , 2012, Immunology and cell biology.

[20]  R. Gomariz,et al.  RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: immune regulation by vasoactive intestinal peptide. , 2011, Arthritis and rheumatism.

[21]  A. Puig-Kröger,et al.  Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. , 2011, Blood.

[22]  W. Mosgoeller,et al.  Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients , 2010, Peptides.

[23]  A. Puig-Kröger,et al.  Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. , 2009, Cancer research.

[24]  J. Edwards,et al.  Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.

[25]  C. Martínez,et al.  VIP reverses the expression profiling of TLR4-stimulated signaling pathway in rheumatoid arthritis synovial fibroblasts. , 2008, Molecular immunology.

[26]  C. Tsatsanis,et al.  Vasoactive intestinal peptide suppresses toll-like receptor 4 expression in macrophages via Akt1 reducing their responsiveness to lipopolysaccharide. , 2008, Molecular immunology.

[27]  R. Gomariz,et al.  Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. , 2008, Arthritis and rheumatism.

[28]  Javier Martín,et al.  Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. , 2008, Arthritis and rheumatism.

[29]  Mario Delgado,et al.  Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy , 2007, Annals of the rheumatic diseases.

[30]  P. Preshaw,et al.  Pivotal Advance: Vasoactive intestinal peptide inhibits up‐regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages , 2007, Journal of leukocyte biology.

[31]  C. Martínez,et al.  VIP–PACAP System in Immunity , 2006, Annals of the New York Academy of Sciences.

[32]  C. Martínez,et al.  VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. , 2006, Rheumatology.

[33]  T. Ottenhoff,et al.  Phenotypic and functional profiling of human proinflammatory type‐1 and anti‐inflammatory type‐2 macrophages in response to microbial antigens and IFN‐γ‐ and CD40L‐mediated costimulation , 2006, Journal of leukocyte biology.

[34]  A. Couvineau,et al.  VPAC receptors for VIP and PACAP. , 2002, Receptors & channels.

[35]  Mario Delgado,et al.  Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease , 2001, Nature Medicine.

[36]  M. O'dorisio,et al.  Selective Gene Expression and Activation-Dependent Regulation of Vasoactive Intestinal Peptide Receptor Type 1 and Type 2 in Human T Cells1 , 2001, The Journal of Immunology.

[37]  M. Delgado,et al.  Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Nuclear Factor-κB-dependent Gene Activation at Multiple Levels in the Human Monocytic Cell Line THP-1* , 2001, The Journal of Biological Chemistry.

[38]  M. Delgado,et al.  Immunology of VIP: a review and therapeutical perspectives. , 2000, Current pharmaceutical design.

[39]  M. Delgado,et al.  Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. , 2001, The Journal of biological chemistry.

[40]  E. Muñoz-Elías,et al.  VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cells , 1999, Journal of Neuroimmunology.

[41]  E. Muñoz-Elías,et al.  Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. , 1999, Journal of immunology.

[42]  E. Muñoz-Elías,et al.  Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor α Transcriptional Activation by Regulating Nuclear Factor-kB and cAMP Response Element-binding Protein/c-Jun* , 1998, The Journal of Biological Chemistry.

[43]  M. Goldman,et al.  The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. , 1998, Immunology letters.